FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147081693> ?p ?o ?g. }

• W2147081693 endingPage "248" @default.
• W2147081693 startingPage "241" @default.
• W2147081693 abstract "HomeHypertensionVol. 49, No. 2Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBRole of Oxidative Stress in Cardiac Hypertrophy and Remodeling Eiki Takimoto and David A. Kass Eiki TakimotoEiki Takimoto From the Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Md. Search for more papers by this author and David A. KassDavid A. Kass From the Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Md. Search for more papers by this author Originally published26 Dec 2006https://doi.org/10.1161/01.HYP.0000254415.31362.a7Hypertension. 2007;49:241–248Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: December 26, 2006: Previous Version 1 Cardiac adaptation in response to intrinsic or external stress involves a complex process of chamber remodeling and myocyte molecular modifications. A fundamental response to increased biomechanical stress is cardiomyocyte and chamber hypertrophy. Although this may provide initial salutary compensation to the stress, sustained hypertrophic stimulation becomes maladaptive, worsening morbidity and mortality risks because of congestive heart failure and sudden death.1 Growing evidence highlights oxidative and nitrosative stresses as important mechanisms for this maladaptation.2–9 Oxidative stress occurs when excess reactive oxygen species (ROS) are generated that cannot be adequately countered by intrinsic antioxidant systems. Superoxide anion (O2−) can further combine with NO, forming reactive compounds such as peroxynitrite, generating nitroso-redox imbalance.4 ROS generation is a normal component of oxidative phosphorylation and plays a role in normal redox control of physiological signaling pathways.5,8,9 However, excessive ROS generation triggers cell dysfunction, lipid peroxidation, and DNA mutagenesis and can lead to irreversible cell damage or death.5,8,9 In this review, we discuss recent experimental evidence for the role of oxidant stress on cardiac remodeling, focusing on pressure- overload–induced hypertrophy and dilation.ROS, Antioxidant Enzymes, and Nitroso-Redox BalanceROS include free radicals such as superoxide (O2−) and hydroxyl radical and compounds such as hydrogen peroxide (H2O2) that can be converted to radicals, and they participate in both normal and pathologic biochemical reactions.9 O2− is formed intracellularly (Figure 1) by activation of nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase or xanthine oxidase (XO), uncoupling of NO synthase (NOS), and electron transport and “leakage” during oxidative phosphorylation in the mitochondria.5,8,9 H2O2 can generate the highly reactive hydroxyl radical via Fenton chemistry under pathological conditions.9Download figureDownload PowerPointFigure 1. General schematic of generation pathways for ROS and antioxidant systems in the heart. Low levels of ROS are thought to play a role in normal cardiac signaling, growth adaptations, and matrix changes. Higher levels play a role in pathophysiologic remodeling, apoptosis, and chamber dysfunction. SOD indicates superoxide dismutase; GPX, glutathione peroxidase; TRX, thioredoxin.Cells also have intrinsic antioxidant systems that counter ROS accumulation. These include enzymes such as catalase, glutathione peroxidases, and superoxide dismutase, and nonenzymatic antioxidants, such as vitamins E, C, beta carotene, ubiquinone, lipotic acid, and urate.9,10 Superoxide dismutase converts O2− to H2O2, which is further converted by catalase and glutathione peroxidase to water. The thioredoxin system, including thioredoxin, thioredoxin reductase, and NADPH, forms an additional integrated antioxidant defense system, which operates as a powerful protein–disulfide oxidoreductase.10–12NO is another important reactive molecule controlling cardiovascular homeostasis. NO stimulates the synthesis of intracellular cGMP by activating soluble guanylyl cyclase, and cGMP and its target kinase cGK-1 (protein kinase G 1), in turn, modulate myocyte function, growth, and remodeling.13 NO also interacts with proteins via S-nitrosylation at specific cysteine residues to alter their function.14,15 S-nitosylation is facilitated by O2− at physiological levels; however, this process is inhibited at high levels of O2−.9 As noted, increased O2− interacts with NO to form peroxynitrite, a reactive species that is capable of triggering an array of cytotoxic processes, including lipid peroxidation, protein oxidation, and nitration (altering excitation–contraction coupling),16 and activation of matrix metalloproteinases (MMPs) contributing to chamber remodeling (reviewed in References17,18). NO can act as an antioxidant, inhibiting activation of XO19,20 and NADPH oxidase21,22 and maintaining normal O2−/NO homeostasis. Thus, increasing peroxynitrite levels means that normal NO bioavailability and physiology would be compromised.Mechanisms for ROS Stimulation of Cardiac Hypertrophy/RemodelingFigure 2 summarizes the mechanisms by which ROS stimulate myocardial growth, matrix remodeling, and cellular dysfunction. ROS activate a broad variety of hypertrophy signaling kinases and transcription factors.23 In rat neonatal cardiomyocytes, H2O2 stimulates the tyrosine kinase Src, GTP-binding protein Ras, protein kinase C, mitogen-activated protein kinases (extracellular response kinase and extracellular signal–regulated kinase), and Jun-nuclear kinase.24–26 Phosphoinositol 3-kinase is required for H2O2-induced hypertrophy.27 Low levels of H2O2 are associated with extracellular signal–regulated kinase activation and protein synthesis, whereas higher levels stimulate extracellular signal–regulated kinase, Jun-nuclear kinase, p38, and Akt kinases to induce apoptosis.28 ROS also play an important role in G protein–coupled hypertrophic stimulation by angiotensin II and α-adrenergic stimulation,29–33 the latter involving oxidative modulation of Ras thiols.34 ROS also stimulate cellular apoptosis signaling kinase-1, a redox-sensitive kinase upstream of Jun-nuclear kinase and p38. Apoptosis signaling kinase-1 overexpression activates nuclear factor κB to stimulate hypertrophy, whereas genetic silencing of apoptosis signaling kinase-1 inhibits hypertrophy induced by angiotensin II, norepinephrine, and endothelin I.35Download figureDownload PowerPointFigure 2. Molecular signaling pathways linking ROS to cardiac hypertrophy and remodeling. Pathways include calcium channels (ICa), α and β adrenergic (αAR and βAR), angiotensin II (AT1) receptor agonism, modification of stress kinases, collagen and metalloproteinases, sarcomeric and excitation-contraction coupling proteins, and nuclear transcription factors. Details are provided in text. MAPK indicates mitogen-activated protein kinases; PI3K, phosphoinositol 3-kinase; Ask-1, apoptosis signaling kinase-1; PKC, protein kinase C; NFκB, nuclear factor κB; AP-1, activator protein-1.ROS also have potent effects on the extracellular matrix, stimulating cardiac fibroblast proliferation36 and activating MMPs,37–39 effects central to fibrosis and matrix remodeling. MMPs are generally secreted in an inactive form and are activated posttranslationally by ROS from targeted interactions with critical cysteines in the propeptide autoinhibitory domain.40 ROS also stimulate transcription factors nuclear factor κB, Ets, and activator protein-1 to stimulate MMP expression.38Cardiomyocyte apoptosis is another important contributor to hypertrophic remodeling and cell dysfunction.41 For example, mice lacking apoptosis signaling kinase-1 display both reduced ventricular remodeling in response to pressure load or after myocardial infarction (MI) and less cellular apoptosis.42 Apoptosis is inhibited in cells at low levels of ROS stimulation, whereas the opposite occurs at higher levels.28 Mechanisms include DNA and mitochondrial damage and activation of proapoptotic signaling kinases.Lastly, ROS directly influence contractile function by modifying proteins central to excitation–contraction coupling (reviewed in Reference 43). This includes modification of critical thiol groups (-SH) groups on the ryanodine receptor to enhance its open probability,44 suppression of L-type calcium channel current,45 and oxidative and nitrosative interaction with the sarcoplasmic reticular Ca2+ ATPase to inhibit Ca2+ uptake.46,47NOS3 Uncoupling: A Pathophysiologic ROS GeneratorNOS3, or endothelial NOS, has not been traditionally considered a major oxidase, yet recent evidence suggests this function in cardiovascular pathologic remodeling (Figure 3).48–51 NOS3 normally generates NO to stimulate cGMP and cGK-1, which blunt cellular cardiac hypertrophy and fibrosis via transcriptional regulation, phosphorylation, and suppression of targeted signaling, such as from Gαq stimulation.52–58 In mice exposed to sustained pressure overload, chronic inhibition of cGMP hydrolysis by phosphodiesterase 5A induced protein kinase G activation and attenuated chamber and myocyte hypertrophy and fibrosis coupled to inhibition of multiple hypertrophic cascades.59 ROS impede this regulation by reacting with NO to form peroxynitrite, stimulating nitrosative stress and reducing NO bioactivity, limiting soluble guanylate cyclase activity and expression.60 In this setting, NOS3 can generate O2− instead of NO.61Download figureDownload PowerPointFigure 3. Involvement of NOS3 and NOS3 uncoupling in cardiac hypertrophy and remodeling. The normal (coupled) eNOS pathway is shown to the right and is thought to provide an inhibitory influence on hypertrophy and hypertrophic signaling, MMP activation, and cardiac dysfunction. sGC indicates soluable guanylate cyclase; PKG, protein kinase G; Trx, thioredoxin. In the presence of oxidant stress, depletion of substrate (arginine), or cofactors (BH4), NOS can become uncoupled and generate more ROS. This enhanced ROS diverts NO (forming peroxynitirite) and stimulates pathologic cardiac remodeling.Under normal conditions, NOS3 consumes NADPH and generates NO and l-citrulline from l-arginine and O2. In this process, electrons are passed from a reductase domain to the heme-containing oxygenase domain (catalytic core). The cofactor tetrahydrobiopterin (BH4) is essential for donating an electron and proton to versatile intermediates in this reaction cycle. Calmodulin controls the shuttling of the electrons, and a zinc-thiolate complex, as well as BH4, is required for NOS dimer formation and stability of the oxidase domain.62,63 NOS functions normally as a homodimer, and BH4 is required to maintain its “coupled” state and, thus, to synthesize NO.When exposed to oxidative or nitrosative stress or when deprived of BH4 or l-arginine, NOS3 becomes structurally unstable. On protein gels, it appears more as a monomer, and electrons become diverted to molecular oxygen rather than to l-arginine, resulting in O2− formation (uncoupled state).64–66 This change was first reported in the vasculature and has been linked to the endothelial pathophysiology in hypertension, diabetes, smoking, and atherosclerosis.48,50,51,67–70 We reported recently that similar mechanisms also play a key role in the adverse remodeling resulting from chronic pressure overload.49 Hearts exposed to trans-aortic constriction developed marked chamber dilation with decreased NOS3 dimer in the myocardium and elevation of oxidative stress. The latter was reduced by half by preincubating myocardial extract with the NOS inhibitor, NG-nitro-l-arginine methyl ester, suggesting that ROS were being generated by NOS itself. Similarly, animals genetically lacking NOS3 exposed to pressure overload developed more modest and compensated concentric hypertrophy, with little cavity dilation, less interstitial fibrosis, and far less oxidative stress.A major factor that may mediate NOS3 uncoupling in pressure-overloaded hearts is a decline in BH4 levels. This is supported by both direct BH4 measurements and findings that BH4 supplementation offsets the hypertrophic/dilative phenotype.49 Hearts with increased ROS because of uncoupled NOS3 have increased MMP activation, which, in turn, degraded extracellular matrix, facilitating left ventricular dilatation49,71,72 and worsening cardiac function.Given that NOS3 is expressed in vascular endothelium and myocytes, with the latter representing <20 of total myocardial NOS3, it is unclear which cell type contributes most to ROS generated by NOS3 uncoupling. Furthermore, the exact mechanisms leading to NOS3 uncoupling and a reduction in BH4 levels remain unknown. One possibility reported by Landmesser et al51 is that initial oxidant stress (O2−) from NADPH oxidase enhances BH4 oxidization resulting in NOS3 uncoupling. In their study, oral supplementation with BH4 or genetic depletion of NADPH oxidase prevented uncoupling. As NADPH-dependent ROS generation increases in pressure-overload hypertrophy,73 a similar scenario may apply. The interaction between NOS3 uncoupling and BH4 is somewhat circular; NOS3 can become an O2− generator without BH4 depletion,48 and the consequent ROS can, in turn, oxidize BH4 to worsen the process. Evidence of the latter was shown by Bendall et al,74 who generated stoichiometric discordance between NOS3 protein and BH4 levels by comparing endothelial-targeted overexpression of GTP cyclohydrolase 1 ([GTPCH-1] rate-limiting BH4 synthetic enzyme), NOS3, and their combination. Imbalance between BH4 and NOS3 resulted in NOS3 uncoupling. The relative role of these mechanisms may depend on the nature and/or stage of the pathology. For example, NOS3 expression increases in cardiomyopathic hamsters75 and decreases in ischemic cardiomyopathy.76 BH4 depletion can occur by reduced synthesis, particularly related to changes in GTPCH-1, or by the salvage pathway that uses sepiapterin as an intermediate.77 Neopterin, a byproduct of BH4 synthesis by GTPCH-1, declines with pressure-load hypertrophy, suggesting that BH4 biosynthesis is diminished.49 Although studies on the regulation of GTPCH-1 and its role in the myocardium have yet to be reported, recent data showing that signal transducer and activator of transcription-3 activation in endothelial cells lowers GTPCH-1 expression78 suggest a potential mechanism, because signal transducer and activator of transcription-3 is potently activated by pressure overload in the heart.79NADPH OxidasesNADPH oxidases (Figure 4A) are multimeric enzymes that consist of the membrane-bound flavocytochrome composing a catalytic Nox subunit and p22phox subunit, and 4 cytosolic regulatory subunits, p40phox, p47phox, p67phox, and the small GTP-binding protein Rac.80 Electron transfer occurs from NADPH to molecular oxygen at the catalytic site, resulting in the formation of superoxide. There are 5 Nox isoforms (Nox1–5), expressed in a tissue-specific manner. Among these, Nox2 (known previously as gp91phox) and Nox4 are the main isoforms expressed in the myocardium.5 NADPH oxidase activity increases from stimuli such as angiotensin II,81,82 cyclic load,83,84 α-adrenergic agonists,85 and tumor necrosis factor-α.86 NADPH oxidase activity and subunit expression increase during the development of pressure-overload hypertrophy in guinea pigs73 and human heart failure.87,88 ROS derived from NADPH oxidases can induce NOS3 uncoupling (as discussed above) and activate XO,89 thus, the NADPH oxidases may serve as priming sources for amplification of ROS generation. Download figureDownload PowerPointFigure 4. A, Role of NADPH oxidases in cardiac response to pressure overload, angiotensin stimulation, and myocardial infarction. Nox2 has been found to play a role in angiotensin-stimulated hypertrophy, but its genetic absence does not prevent pressure-load–induced hypertrophy. Other influences on fibrosis and contractile function, however, have been observed. Nox4 may contribute to pressure-load hypertrophy, but this has not been clarified to date. B, Role of XO system in heart failure and, potentially, pressure overload. Increased XO activity has been observed in various animal heart failure models, and its inhibition can improve contraction and energetic efficiency. C, Proposed interaction between XO and neuronal NOS (nNOS) in modifying calcium handling by the ryanodine receptor and contractile function. Genetic loss of NOS1 can result in increased XO and O2− generation, inhibiting calcium handling and leading to contractile dysfunction.ROS generated by NADPH oxidase seem to play a key role to angiotensin II–induced cardiac hypertrophy/remodeling. Subpressor doses of angiotensin II induce cardiac hypertrophy that is blunted in hearts lacking Nox2.90 In addition, Rac1 null mice have reduced NADPH oxidase activity, associated with lower myocardial oxidative stress, blunted hypertrophy, and less activation of apoptosis signaling kinase-1 and nuclear factor κB in response to angiotensin II infusion.91 Nox2 null hearts also display less remodeling after MI.92 However, mice lacking Nox2 develop similar hypertrophic responses to pressure overload as in controls but with less fibrosis and better cardiac contraction.93–95 Thus, alternative pathways and/or Nox isoforms (eg, Nox4) may be more relevant in this setting.Xanthine OxidaseRecent experimental data suggest that XO and XO-related oxidant stress also play a role in the pathogenesis of chronic heart failure (Figure 4B and 4C). Elevated XO expression and activity have been demonstrated in end-stage human heart failure96 and in the canine rapid pacing-induced heart failure model.97,98 Chronic treatment with allopurinol significantly reduced adverse left ventricular remodeling99 and modestly improved survival100 in mice after MI or rats with dilated cardiomyopathy.101 Allopurinol also prevented myofibrillar protein oxidization and preserved cardiac function in transgenic mice harboring truncated troponin I, a model of myocardial stunning.102Interestingly, XO-derived superoxide seems to interfere with NO regulation of myocardial energetics.103 Khan et al104 reported that neuronal NOS (NOS1 or nNOS) and the superoxide generating xanthine oxidoreductase lie in physical proximity in the sarcoplasmic reticulum of cardiac myocytes. Deficiency of NOS1 increased xanthine oxidoreductase–mediated superoxide production, negatively regulating cardiac contractility, and this was reversible by allopurinol. The same group reported that NOS1 null hearts had worse remodeling and cardiac function than wild-type after myocardial infarct; however, surprisingly, tissue ROS levels increased similarly in either genotype.105 Importantly, they found different NO levels in heart tissues (increase in wild-type but not in NOS1 null hearts), suggesting that the imbalance between NOS1-mediated NO signaling and ROS, rather than the ROS level itself, was more important. Increased XO activity has been reported in late-stage pressure-overload–induced right ventricular hypertrophy.106Mitochondrial ROSExcessive ROS derived from mitochondria are also likely contributors to cardiac failure (reviewed in Reference 107) and have also been reported in experimental models of MI and heart failure (eg, tachypacing-induced failure108,109). This has been attributed to electron leakage associated with reduced activity in electron transport chain complexes and can be a source for O2−, H2O2, and OH−. This oxidative stress plays an initial role in damaging mitochondrial DNA and organelle function and can result in membrane potential abnormalities, ROS leakage, and cellular damage. Overexpression of the mitochondrial antioxidant, peroxiredoxin-3, ameliorates mitochondrial DNA damage and inhibits adverse left ventricular remodeling after MI.110 However, the specific role of ROS from mitochondria in pressure-overload–induced hypertrophy has not been reported to date and awaits further elucidation.Antioxidant Systems and Pressure OverloadSeveral intrinsic antioxidants have been shown to ameliorate the evolution of heart failure or hypertrophy in experimental models. For example, chronic treatment with the nonspecific antioxidant vitamin E improved cardiac function and blunted heart failure in a guinea pig pressure-overload model,111 although an antihypertrophic effect was not observed. 2N-merocaptoproninyl glycine or N-acetyl cysteine blunted cardiac hypertrophy in mice with pressure overload.93,112 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin also can act as an antioxidant and has been shown to prevent in vitro cardiomyocyte and in vivo pressure-overload–induced hypertrophy linked to inhibition of Rac1 and, thus, reduction of NADPH oxidase activity.113Enzyme antioxidant pathways have been genetically manipulated to reveal a prominent role in hypertrophic remodeling. Thioredoxin is a ubiquitous thiol oxidoreductase composed of thioredoxin, thioredoxin reductase, and NADPH and limits oxidative stress by direct ROS scavenging and by interaction with other signaling kinases.12 Inhibition of endogenous thioredoxin-1 results in enhanced cardiac hypertrophy with increased myocardial oxidative stress to pressure overload, whereas overexpression of the protein reduces hypertrophy and oxidative stress.11 Interestingly, thioredoxin is upregulated by cGMP/protein kinase G in human neuroblastoma cells, protecting cells from oxidative stress–induced apoptosis.114 A similar mechanism might play a role in NO/cGMP/protein kinase G–mediated amelioration of cardiac hypertrophy/remodeling (Figure 3). Another intrinsic antioxidant enzyme, glutathione peroxidase, important for removing H2O2 and detoxifying lipid hydroperoxides, has also been overexpressed in mouse heart, and this ameliorated post-MI remodeling.115Targeting Oxidative/Nitrosative Stress: A Clinical StrategyAlthough recent basic experimental studies strongly support a key role of oxidative/nitrosative stress in the pathophysiology of cardiac hypertrophic remodeling and dysfunction, clinical data testing these findings remain scant. Although small, often uncontrolled clinical studies have been supportive, larger prospective and randomized, controlled trials have failed to show clinical benefit from antioxidants such as vitamin C and vitamin E.116–118 However, these studies have not examined hypertrophic heart disease or heart failure, per se, and the bulk of the data, which are from cancer trials, may not predict cardiac disease responses. Recent clinical trials of allopurinol and oxypurinol to treat class II to III congestive heart failure found reduced plasma urate yet no impact on clinical outcome.119 However, angiotensin-converting enzyme inhibitors, the β-blocker carvedilol, and angiotensin receptor blockers can block NADPH oxidase, whereas statins inhibit Rac1 and, thus, NADPH oxidase, and this may contribute to part of their efficacy. More specific targeting of the source of oxidative stress, such as recoupling of NOS or enhancing intrinsic antioxidants,120 may ultimately provide more effective approaches to reversing cardiac remodeling. BH4 and its precursor sepiapterin are well tolerated and are currently used to treat some forms of the genetic disease phenylketonuria in humans.121 The experimental data seem compelling, and it seems premature to abandon this tactic for clinical treatment. Further studies using more potent and better-targeted agents will hopefully establish their use in the future.Sources of FundingSupported by Peter Belfer Laboratory Endowment PO1H077180, AG18324, and PO1HL59408 (D.A.K.) and American Heart Association SDG Award (E.T.).DisclosuresNone.FootnotesCorrespondence to David A. Kass, Ross 835, 720 Rutland Ave, Johns Hopkins Medical Institutions, Baltimore, MD 21205. E-mail [email protected] References 1 Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003; 65: 45–79.CrossrefMedlineGoogle Scholar2 McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 1993; 14: 1493–1498.CrossrefMedlineGoogle Scholar3 Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998; 31: 1352–1356.CrossrefMedlineGoogle Scholar4 Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest. 2005; 115: 509–517.CrossrefMedlineGoogle Scholar5 Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res. 2006; 71: 208–215.CrossrefMedlineGoogle Scholar6 Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998; 97: 1536–1539.CrossrefMedlineGoogle Scholar7 Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Antelli A, Canistro D, Francolini G, Macri G, Mastrorilli F, Paolini M, Ferrari R. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004; 43: 2000–2008.CrossrefMedlineGoogle Scholar8 Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002; 34: 379–388.CrossrefMedlineGoogle Scholar9 Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005; 115: 500–508.CrossrefMedlineGoogle Scholar10 Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med. 2001; 31: 1287–1312.CrossrefMedlineGoogle Scholar11 Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest. 2003; 112: 1395–1406.CrossrefMedlineGoogle Scholar12 Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res. 2003; 93: 1029–1033.LinkGoogle Scholar13 Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res. 2003; 93: 907–916.LinkGoogle Scholar14 Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med. 2004; 351: 2112–2114.CrossrefMedlineGoogle Scholar15 Paolocci N, Ekelund UE, Isoda T, Ozaki M, Vandegaer K, Georgakopoulos D, Harrison RW, Kass DA, Hare JM. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ Physiol. 2000; 279: H1982–H1988.CrossrefMedlineGoogle Scholar16 Katori T, Donzelli S, Tocchetti CG, Miranda KM, Belardi DF, Cormaci G, Thomas DD, Ketner EA, Lee MJ, Mancardi D, Wink DA, Kass DA, Paolocci N. Peroxnitrite and myocardial contractility: in vivo versus in vitro effects. Free Radic Biol Med. 2006; 41: 1606–1618.CrossrefMedlineGoogle Scholar17 Turko IV, Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev. 2002; 54: 619–634.CrossrefMedlineGoogle Scholar18 Pacher P, Schulz R, Liaudet L, Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci. 2005; 26: 302–310.CrossrefMedlineGoogle Scholar19 Hassoun PM, Yu FS, Zulueta JJ, White AC, Lanzillo JJ. Effect of nitric oxide and cell redox status on the regulation of endothelial cell xanthine dehydrogenase. Am J Physiol. 1995; 268: L809–L817.MedlineGoogle Scholar20 Cote CG, Yu FS, Zulueta JJ, Vosatka RJ, Hassoun PM. Regulation of intracellular xanthine oxidase by endothelial-derived nitric oxide. Am J Physiol. 1996; 271: L869–L874.CrossrefMedlineGoogle Scholar21 Shinyashiki M, Pan CJ, Lopez BE, Fukuto JM. Inhibition of the yeast metal reductase heme protein fre1 by nitric oxide (NO): a model for inhibition of NADPH oxidase by NO. Free Radic Biol Med. 2004; 37: 713–723.CrossrefMedlineGoogle Scholar22 Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 1992; 90: 1116–1121.CrossrefMedlineGoogle Scholar23 Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal. 2003; 5: 731–740.CrossrefMedlineGoogle Scholar24 Wei S, Rothstein EC, Fliegel L, Dell’Italia LJ, Lucchesi PA. Differential MAP kinase activation and Na(+)/H(+) exchanger phosphorylation by H(2)O(2) in rat cardiac myocytes. Am J Physiol Cell Physiol. 2001; 281: C1542–C1550.CrossrefMedlineGoogle Scholar25 Sabri A, Byron KL, Samarel AM, Bell J, Lucchesi PA. Hydrogen peroxide activates mitogen-activated protein kinases and Na+-H+ exchange in neonatal rat cardiac myocytes. Circ Res. 1998; 82: 1053–1062.CrossrefMedlineGoogle Scholar26 Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, Hasegawa H, Akazawa H, Mizukami M, Nagai R, Komuro I. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Bio" @default.
• W2147081693 created "2016-06-24" @default.
• W2147081693 creator A5057515883 @default.
• W2147081693 creator A5081031540 @default.
• W2147081693 date "2007-02-01" @default.
• W2147081693 modified "2023-10-10" @default.
• W2147081693 title "Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling" @default.
• W2147081693 cites W113714250 @default.
• W2147081693 cites W1483108854 @default.
• W2147081693 cites W1551392207 @default.
• W2147081693 cites W1678920698 @default.
• W2147081693 cites W1837902822 @default.
• W2147081693 cites W1967970013 @default.
• W2147081693 cites W1968995777 @default.
• W2147081693 cites W1969968096 @default.
• W2147081693 cites W1972806200 @default.
• W2147081693 cites W1974358158 @default.
• W2147081693 cites W1974614602 @default.
• W2147081693 cites W1975597097 @default.
• W2147081693 cites W1978545009 @default.
• W2147081693 cites W1979707331 @default.
• W2147081693 cites W1980322984 @default.
• W2147081693 cites W1981905227 @default.
• W2147081693 cites W1987037786 @default.
• W2147081693 cites W1995444906 @default.
• W2147081693 cites W1998986492 @default.
• W2147081693 cites W2003145436 @default.
• W2147081693 cites W2006330191 @default.
• W2147081693 cites W2006659891 @default.
• W2147081693 cites W2006847107 @default.
• W2147081693 cites W2011089437 @default.
• W2147081693 cites W2011780678 @default.
• W2147081693 cites W2013105469 @default.
• W2147081693 cites W2014779837 @default.
• W2147081693 cites W2015030290 @default.
• W2147081693 cites W2022265177 @default.
• W2147081693 cites W2030165232 @default.
• W2147081693 cites W2030437438 @default.
• W2147081693 cites W2030541456 @default.
• W2147081693 cites W2030929060 @default.
• W2147081693 cites W2032634942 @default.
• W2147081693 cites W2032715878 @default.
• W2147081693 cites W2036718044 @default.
• W2147081693 cites W2036722319 @default.
• W2147081693 cites W2041543005 @default.
• W2147081693 cites W2041956415 @default.
• W2147081693 cites W2042221596 @default.
• W2147081693 cites W2044443940 @default.
• W2147081693 cites W2045282478 @default.
• W2147081693 cites W2049636133 @default.
• W2147081693 cites W2051441972 @default.
• W2147081693 cites W2056584805 @default.
• W2147081693 cites W2058242086 @default.
• W2147081693 cites W2060275872 @default.
• W2147081693 cites W2063024150 @default.
• W2147081693 cites W2063481915 @default.
• W2147081693 cites W2067902287 @default.
• W2147081693 cites W2079509424 @default.
• W2147081693 cites W2080961720 @default.
• W2147081693 cites W2082452850 @default.
• W2147081693 cites W2084593725 @default.
• W2147081693 cites W2090881549 @default.
• W2147081693 cites W2094806874 @default.
• W2147081693 cites W2099120495 @default.
• W2147081693 cites W2099136646 @default.
• W2147081693 cites W2102564608 @default.
• W2147081693 cites W2102619095 @default.
• W2147081693 cites W2107031860 @default.
• W2147081693 cites W2109429191 @default.
• W2147081693 cites W2114425457 @default.
• W2147081693 cites W2115538102 @default.
• W2147081693 cites W2115993532 @default.
• W2147081693 cites W2117383015 @default.
• W2147081693 cites W2117489997 @default.
• W2147081693 cites W2117596573 @default.
• W2147081693 cites W2119223703 @default.
• W2147081693 cites W2126129355 @default.
• W2147081693 cites W2129048293 @default.
• W2147081693 cites W2129439677 @default.
• W2147081693 cites W2130999379 @default.
• W2147081693 cites W2133272765 @default.
• W2147081693 cites W2139473520 @default.
• W2147081693 cites W2139533485 @default.
• W2147081693 cites W2142986295 @default.
• W2147081693 cites W2148048443 @default.
• W2147081693 cites W2161189845 @default.
• W2147081693 cites W2162856150 @default.
• W2147081693 cites W2163582362 @default.
• W2147081693 cites W2165073849 @default.
• W2147081693 cites W2165537841 @default.
• W2147081693 cites W2167151063 @default.
• W2147081693 cites W2168267395 @default.
• W2147081693 cites W2168595038 @default.
• W2147081693 cites W2170474257 @default.
• W2147081693 cites W2170551438 @default.
• W2147081693 cites W2171466485 @default.
• W2147081693 cites W2194462879 @default.
• W2147081693 cites W2306020621 @default.

• next